The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential
Article
Article Title | The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential |
---|---|
ERA Journal ID | 15238 |
Article Category | Article |
Authors | Kroon, Paul A. (Author), Iyer, Abishek (Author), Chunduri, Prasad (Author), Chan, Vincent (Author) and Brown, Lindsay (Author) |
Journal Title | Current Medicinal Chemistry |
Journal Citation | 17 (23), pp. 2442-2455 |
Number of Pages | 14 |
Year | 2010 |
Place of Publication | Bussum, Netherlands |
ISSN | 0929-8673 |
1875-533X | |
Digital Object Identifier (DOI) | https://doi.org/10.2174/092986710791556032 |
Abstract | Red wine contains many compounds that may have therapeutic use, including resveratrol (3,4',5-trihydroxy- trans-stilbene). Since resveratrol could be administered both in the diet and as a therapeutic agent, defining appropriate concentrations requires understanding of the pharmacokinetics. Resveratrol absorption is rapid but plasma concentrations are low as it is rapidly and efficiently converted into relatively hydrophilic phase-2 conjugates, and metabolites, which are then rapidly excreted via the urine and bile. Resveratrol is an effective antioxidant in vivo by increasing NO synthesis and also maintaining the reduced intracellular redox state via the thioredoxin system. Further, activation of sirtuins (one class of lysine deacetylases) may mediate the cardiovascular responses shown by resveratrol. Studies on animal models of hu- man disease suggest that resveratrol has the potential to decrease cardiovascular symptoms in patients with myocardial in- farction, arrhythmias, hypertension, cardiomyopathies, fibrosis, atherosclerosis, thrombosis and diabetes, but, as yet, human clinical trials are rare. Cardioprotection by resveratrol in rodent models may rely on mechanisms producing pharmacological preconditioning in the heart including reducing reactive oxygen species, improving vasorelaxation and angigenesis, preventing inflammation and apoptosis, delaying atherosclerosis as well as decreasing cardiovascular remodel- ling. Interventional studies in humans need to be completed before resveratrol can be considered as a standard therapeutic agent. Therefore, future studies should focus on obtaining the level of evidence required to determine whether resveratrol can be added to the list of evidence-based therapies for cardiovascular diseases that includes renin-angiotensin system inhibitors, adrenoceptor antagonists and calcium entry blockers. |
Keywords | resveratrol; sirtuins; preconditioning; cardiovascular remodelling |
ANZSRC Field of Research 2020 | 320199. Cardiovascular medicine and haematology not elsewhere classified |
320599. Medical biochemistry and metabolomics not elsewhere classified | |
321401. Basic pharmacology | |
Public Notes | Files associated with this item cannot be displayed due to copyright restrictions. |
Byline Affiliations | Quadram Institute, United Kingdom |
University of Queensland | |
Department of Biological and Physical Sciences |
https://research.usq.edu.au/item/q0091/the-cardiovascular-nutrapharmacology-of-resveratrol-pharmacokinetics-molecular-mechanisms-and-therapeutic-potential
1998
total views9
total downloads0
views this month0
downloads this month